T Cell Immunity and Zika Virus Vaccine Development

2017 ◽  
Vol 38 (8) ◽  
pp. 594-605 ◽  
Author(s):  
Noemia S. Lima ◽  
Morgane Rolland ◽  
Kayvon Modjarrad ◽  
Lydie Trautmann
Keyword(s):  
T Cell ◽  
Virus Vaccine ◽  
Zika Virus ◽  
Vaccine Development ◽  
T Cell Immunity ◽  
Cell Immunity

scholarly journals T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

2017 ◽  
Vol 137 ◽  
pp. 82-92 ◽  
Author(s):  
William J. Liu ◽  
Min Zhao ◽  
Kefang Liu ◽  
Kun Xu ◽  
Gary Wong ◽  
...  
Keyword(s):  
T Cell ◽  
Vaccine Development ◽  
T Cell Immunity ◽  
Cell Immunity

scholarly journals The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo

2005 ◽  
Vol 201 (4) ◽  
pp. 567-577 ◽  
Author(s):  
Jianuo Liu ◽  
Takashi Miwa ◽  
Brendan Hilliard ◽  
Youhai Chen ◽  
John D. Lambris ◽  
...  
Keyword(s):  
T Cell ◽  
Vaccine Development ◽  
T Cell Immunity ◽  
Cell Secretion ◽  
Inhibitory Protein ◽  
Cell Immunity ◽  
Ifn Γ ◽  
Eae Model

Decay-accelerating factor ([DAF] CD55) is a glycosylphosphatidylinositol-anchored membrane inhibitor of complement with broad clinical relevance. Here, we establish an additional and unexpected role for DAF in the suppression of adaptive immune responses in vivo. In both C57BL/6 and BALB/c mice, deficiency of the Daf1 gene, which encodes the murine homologue of human DAF, significantly enhanced T cell responses to active immunization. This phenotype was characterized by hypersecretion of interferon (IFN)-γ and interleukin (IL)-2, as well as down-regulation of the inhibitory cytokine IL-10 during antigen restimulation of lymphocytes in vitro. Compared with wild-type mice, Daf1−/− mice also displayed markedly exacerbated disease progression and pathology in a T cell–dependent experimental autoimmune encephalomyelitis (EAE) model. However, disabling the complement system in Daf1−/− mice normalized T cell secretion of IFN-γ and IL-2 and attenuated disease severity in the EAE model. These findings establish a critical link between complement and T cell immunity and have implications for the role of DAF and complement in organ transplantation, tumor evasion, and vaccine development.

scholarly journals Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans

2017 ◽  
Vol 91 (24) ◽  
Author(s):  
Alba Grifoni ◽  
John Pham ◽  
John Sidney ◽  
Patrick H. O'Rourke ◽  
Sinu Paul ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Zika Virus ◽  
T Cell Responses ◽  
Cross Reactivity ◽  
T Cell Response ◽  
T Cell Immunity ◽  
Cell Responses ◽  
Cell Immunity

ABSTRACT While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in DENV-preexposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins. IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of great relevance, as the two viruses often cocirculate and Zika virus has been spreading in geographical regions where DENV is endemic or hyperendemic. Our data show that memory T cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides and that DENV exposure prior to ZIKV infection influences the timing, magnitude, and quality of the T cell response. Additionally, we show that ZIKV-specific responses target different proteins than DENV-specific responses, pointing toward important implications for vaccine design against this global threat.

scholarly journals T cell immunity to Zika virus targets immunodominant epitopes that show cross-reactivity with other Flaviviruses

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
C. J. Reynolds ◽  
O. M. Suleyman ◽  
A. M. Ortega-Prieto ◽  
J. K. Skelton ◽  
P. Bonnesoeur ◽  
...  
Keyword(s):  
T Cell ◽  
Zika Virus ◽  
Cross Reactivity ◽  
T Cell Immunity ◽  
Cell Immunity ◽  
Immunodominant Epitopes

scholarly journals CD4+and CD8+T-cell immunity to Dengue - lessons for the study of Zika virus

Immunology ◽  
2016 ◽  
Vol 150 (2) ◽  
pp. 146-154 ◽  
Author(s):  
Laura Rivino ◽  
Mei Qiu Lim
Keyword(s):  
T Cell ◽  
Zika Virus ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Cell Immunity

scholarly journals Insights into innate and adaptive immune responses in vaccine development against EV-A71

2019 ◽  
Vol 7 ◽  
pp. 251513551988899 ◽  
Author(s):  
Hui Xuan Lim ◽  
Chit Laa Poh
Keyword(s):  
T Cell ◽  
Cellular Immunity ◽  
Vaccine Development ◽  
Foot And Mouth Disease ◽  
T Cell Immunity ◽  
Effective Vaccine ◽  
Cell Immunity ◽  
Causative Agents ◽  
Us Fda

Enterovirus A71 (EV-A71) is one of the major causative agents of hand, foot and mouth disease (HFMD) in the world, infecting mostly infants and young children (<5 years of age) in Asia. Approximately 2 million cases of HFMD were reported in China each year, of which approximately 45–50% were due to EV-A71. Most of the HFMD infections caused by EV-A71 usually result in mild symptoms with rashes and ulcers in the mouth. However, virulent strains of EV-A71 can infect the central nervous system and cause severe neurologic diseases, leading to reduced cognitive ability, acute flaccid paralysis and death. The lack of understanding of cellular immunity for long-term protection from the HFMD disease represents a major obstacle for vaccine development. In particular, the role of innate and T cell immunity during HFMD infection remains unclear and there is evidence suggesting the importance of CD4+ and CD8+ T cells for protective immunity. Currently, no US FDA-approved vaccine is available for EV-A71. Although the inactivated vaccines produced in China are highly effective (vaccine efficacy >95%), they lack the cellular immunity required for long-term protection. In this review, we discuss the findings that support the protective roles of innate and T cell immunity against EV-A71 infection, which will provide the knowledge needed for the urgent development of efficacious vaccines that will confer long-term protection.

scholarly journals Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice

2019 ◽  
Vol 68 (4) ◽  
pp. 533-544 ◽  
Author(s):  
Elodie Pliquet ◽  
Claude Ruffie ◽  
Marie Escande ◽  
Jessie Thalmensi ◽  
Valérie Najburg ◽  
...  
Keyword(s):  
T Cell ◽  
Virus Vaccine ◽  
Measles Virus ◽  
Viral Vector ◽  
T Cell Immunity ◽  
Cell Immunity
Sign in / Sign up

Export Citation Format

Share Document